Press Releases

Date Title and Summary Additional Formats
Toggle Summary Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells
Reimbursement decision expands access to testing that provides critical information used to guide targeted treatment options for patients with breast cancer Company provides updates on other initiatives including CNSide™, its proprietary test for neuro-oncology, and COVID-19 testing volume, which
View HTML
Toggle Summary Biocept Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman
Expanded Board to build on company’s recent successes in oncology diagnostics and COVID-19 testing SAN DIEGO --(BUSINESS WIRE)--Jul. 20, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed Linda Rubinstein and Antonino Morales to
View HTML
Toggle Summary Biocept to Participate in Two July Investment Conferences
SAN DIEGO --(BUSINESS WIRE)--Jul. 19, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall , President and CEO, will participate at the following investment conferences: Brookline Capital Markets Newport
View HTML
Toggle Summary Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer Biomarkers
Expands company’s patent portfolio in pursuit of worldwide intellectual property protection for proprietary technology that detects biomarkers in tissue, blood, and cerebrospinal fluid SAN DIEGO --(BUSINESS WIRE)--Jul. 6, 2021-- Biocept, Inc . (NASDAQ: BIOC), a leading provider of molecular
View HTML
Toggle Summary Biocept Joins the Russell Microcap® Index
SAN DIEGO --(BUSINESS WIRE)--Jun. 28, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will be added to the Russell Microcap Index after the U.S. market opens today, June 28, 2021 .
View HTML
Toggle Summary Biocept to Collaborate with Quest Diagnostics to Provide Advanced NGS-Based Liquid Biopsy Testing for Patients with Lung Cancer
SAN DIEGO --(BUSINESS WIRE)--Jun. 22, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced a collaboration with Quest Diagnostics (NYSE: DGX) to provide laboratory testing services to Quest patients for its Target Selector™
View HTML
Toggle Summary Biocept Receives More Than 420,000 Samples During First Year of Offering COVID-19 Testing Service
SAN DIEGO --(BUSINESS WIRE)--Jun. 15, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it has received more than 420,000 samples for SARS-CoV-2 testing since launching this service in June 2020 .
View HTML
Toggle Summary Biocept and CLEARED4 Collaborate to Develop New Service for Managing COVID-19 Testing and Results Reporting for Biocept Customers
Integrated solution incorporates testing protocols and real-time test results to help ensure safer, healthier campuses, healthcare facilities and other venues SAN DIEGO --(BUSINESS WIRE)--Jun. 9, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and
View HTML
Toggle Summary Biocept to Present at the LD Micro Virtual Invitational XI Conference on June 9, 2021
SAN DIEGO --(BUSINESS WIRE)--Jun. 3, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall , President and CEO, will present at the LD Micro Virtual Invitational XI Conference on June 9, 2021 at 3:00 p.m.
View HTML
Toggle Summary Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO --(BUSINESS WIRE)--Jun. 2, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 144,580 shares of its common stock to eighteen new employees.
View HTML